{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-058152","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.203119+00:00","generated_at":"2026-06-07T11:34:39.520299+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ionis licenses donidalorsen European rights to Otsuka; $65M upfront, tiered royalties","bullets":["Otsuka receives exclusive European commercialization rights to donidalorsen (HAE prophylactic).","Ionis gets $65M upfront plus undisclosed regulatory/sales milestones.","Ionis eligible for tiered royalties of 20-30% on European net sales.","Ionis retains U.S. commercialization rights; plans to launch independently if approved.","Phase 3 donidalorsen data expected H1 2024; Phase 2 OLE showed 96% attack rate reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-058152","json":"https://secwatch.observer/filing/0001140361-23-058152.json","markdown":"https://secwatch.observer/filing/0001140361-23-058152.md","text":"https://secwatch.observer/filing/0001140361-23-058152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036123058152/0001140361-23-058152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036123058152/ef20016866_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:34:39.520299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"edf7476520b9a1ae7e7e1e9c0ae4d771e7916067","claim":"IONIS PHARMACEUTICALS INC entered into a license with Otsuka Pharmaceutical Co., Ltd. (effective 2023-12-18).","evidence_excerpt":"On December 18, 2023, Ionis Pharmaceuticals, Inc. issued a press release announcing it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (“ Otsuka ”) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036123058152/0001140361-23-058152-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Otsuka Pharmaceutical Co., Ltd."},{"label":"Effective","value":"2023-12-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}